F-PKE (3)
UKHGi002-B
General
Cell Line |
|
hPSCreg name | UKHGi002-B |
Cite as: | UKHGi002-B (RRID:CVCL_A1QH) |
Alternative name(s) |
F-PKE (3)
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
UKHGi002-A (F-PKE (2)) |
Last update | 26th April 2022 |
User feedback | |
Provider |
|
Generator | Institute of Human Genetics Heidelberg (UKHG) |
External Databases |
|
BioSamples | SAMEA7390808 |
Cellosaurus | CVCL_A1QH |
Wikidata | Q102115066 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Donor Relations |
|
Other cell lines of this donor | |
All cell lines of this donor's relatives |
Has daughter:
|
External Databases (Donor) |
|
BioSamples | SAMEA7390807 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | simone.berkel@med.uni-heidelberg.de |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Ethic Commission 2 of Heidelberg University, Medical Faculty Mannheim, |
Approval number | 2009-350N-MA |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Ethic Commission 2 of Heidelberg University, Medical Faculty Mannheim, |
Approval number | 2009-350N-MA |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Synonyms
|
Source cell origin |
An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Passage method | Mechanically |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
||||
SOX2 |
Yes |
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
Normal, 46, XY
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.